stockportfolio.pro
PROCEPT BioRobotics Corporation (PRCT)
Healthcare · Medical Devices · NasdaqGM
PROCEPT BioRobotics Corporation revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $7.72M | $34.47M | $75.01M | $136.19M | $224.50M | $308.05M |
| Gross profit | $-1.25M | $15.87M | $37.09M | $71.05M | $137.10M | $196.23M |
| Net income | $-53.02M | $-59.85M | $-87.15M | $-105.90M | $-91.41M | $-95.57M |
| Net margin | -687.0% | -173.6% | -116.2% | -77.8% | -40.7% | -31.0% |
Source: PROCEPT BioRobotics Corporation SEC filings (10-K).
Explore 6 years of PROCEPT BioRobotics Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PRCT in your portfolio →
PROCEPT BioRobotics Corporation financial history by metric
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
PROCEPT BioRobotics Corporation — frequently asked questions
What is PROCEPT BioRobotics Corporation's revenue?
PROCEPT BioRobotics Corporation (PRCT) reported revenue of $308.05M for fiscal year 2025, up 37.2% from the prior year, according to its SEC filings.
Is PROCEPT BioRobotics Corporation profitable?
No — PRCT reported a net loss of $-95.57M in fiscal 2025.
What is PRCT's P/E ratio?
PROCEPT BioRobotics Corporation trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is PROCEPT BioRobotics Corporation growing?
PRCT's revenue grew at roughly 109.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does PROCEPT BioRobotics Corporation have?
As of fiscal year 2025, PRCT carried roughly $51.62M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is PROCEPT BioRobotics Corporation's gross margin?
PRCT's gross margin was 63.7% in fiscal 2025 — gross profit of $196.23M on revenue of $308.05M.
What is PROCEPT BioRobotics Corporation's market cap?
PROCEPT BioRobotics Corporation (PRCT) has a market capitalization of about $1.54B, based on the latest data in our nightly-refreshed cache.
When does PROCEPT BioRobotics Corporation's fiscal year end?
PRCT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from PROCEPT BioRobotics Corporation's official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.